AMGN AMGEN INC
Price Chart
Executive Summary
Canaccord Genuity initiated coverage on AMGN at Hold with a $366 price target, implying 10.4% upside from the current $331.57. The firm's 47% accuracy on 1,538 calls and average 3% return rank it below the top-tier analysts covering this stock. Consensus is mixed: 21 of 44 analysts rate Buy, 20 Hold, and 3 Sell, with a mean target of $352.23. The $366 PT sits above the mean but below the Street high of $427. No upgrades or downgrades were recorded in the past 30 days, but EPS revisions for the current quarter have been negative (18 down vs 3 up). Insider selling was minimal (one $400K sale by a director), and congressional activity shows small mixed trades. The initiation is a neutral-to-slightly-bullish signal from a below-average-accuracy firm, offering limited actionable edge.
Impact Score
Consensus & Targets
Consensus is mixed: 6 Strong Buy, 15 Buy, 20 Hold, 2 Sell, 1 Strong Sell — 48% Buy, 45% Hold, 7% Sell across 44 analysts. The consensus direction is cautiously positive, with a slight lean toward Hold.
Mean PT is $352.23, median $352.50, high $427, low $200. Current price $331.57 implies 6.2% upside to the mean. Canaccord's $366 PT is 3.9% above the mean, indicating a slightly more bullish view than the average analyst.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-14 | Piper Sandler | maintain | Overweight | $427.00 |
| 2026-05-04 | Guggenheim | maintain | Neutral | $340.00 |
| 2026-05-01 | Truist Securities | maintain | Hold | $327.00 |
| 2026-04-21 | Canaccord Genuity | initiate | Hold | $366.00 |
| 2026-04-13 | UBS | maintain | Buy | $400.00 |
| 2026-04-10 | Morgan Stanley | maintain | Equal-Weight | $326.00 |
| 2026-04-09 | Guggenheim | maintain | Neutral | $351.00 |
| 2026-04-08 | Cantor Fitzgerald | reiterate | Neutral | $350.00 |
| 2026-03-10 | Jefferies | initiate | Hold | $350.00 |
| 2026-02-20 | Barclays | initiate | Equal-Weight | $350.00 |
No upgrades or downgrades in the past 30 days. EPS revisions for the current quarter are negative: 18 downward revisions vs 3 upward in the last 30 days, with the current quarter EPS estimate falling from $5.77 to $5.59. Full-year estimates are slightly more stable (19 up vs 11 down).
Firm Track Record — Canaccord Genuity
Canaccord Genuity accuracy: 47% on 1538 calls | avg return: 3%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 13 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| BMO Capital | 100% | 3/3 | 7.1% | top tier |
| Truist Securities | 100% | 3/3 | 4.8% | top tier |
| Mizuho | 100% | 2/2 | 4% | top tier |
| RBC Capital | 88% | 7/8 | 4.9% | top tier |
| Morgan Stanley | 86% | 6/7 | 6.9% | top tier |
| UBS | 86% | 6/7 | 7% | top tier |
| B of A Securities | 80% | 4/5 | 1% | top tier |
| Wells Fargo | 75% | 3/4 | 11.9% | top tier |
| Piper Sandler | 67% | 4/6 | 8% | top tier |
| TD Cowen | 67% | 2/3 | 6.4% | top tier |
Canaccord Genuity has a 47% accuracy rate on 1,538 calls with an average return of 3%, placing it below top-tier firms like BMO Capital (100% on 3 calls, avg return 7.1%) and RBC Capital (88% on 8 calls, avg return 4.9%). Worst-performing firm on AMGN is Barclays (50% on 2 calls, avg return -4.4%).
Earnings Estimates
Next earnings: Aug 3, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0y | $22.41 | $21.70 — $23.01 | $37.8B | ↑3 ↓0 |
| 0q | $5.59 | $4.99 — $6.28 | $9.4B | ↑0 ↓0 |
| +1y | $23.48 | $21.46 — $24.88 | $38.8B | ↑2 ↓0 |
| +1q | $5.76 | $5.06 — $6.15 | $9.7B | ↑0 ↓0 |
Cross-Platform Signals
Insider activity is minimal: one $400K sale by director Grygiel Nancy A. on May 4. Congressional trades show small mixed activity (one buy, three sells). Institutional moves are mixed: Norges Bank added a large new position ($2.16B) but also exited; Renaissance Technologies trimmed 39.7% and exited another fund. Short interest is elevated at 62.1% of TRF volume, signaling bearish positioning. The analyst initiation is neutral and does not converge or diverge strongly with other signals.
Actionable Insight
This is a low-conviction initiation from a below-average-accuracy firm. Traders should not overweight this call; the elevated short interest and negative EPS revisions for the current quarter suggest near-term caution. Wait for a stronger catalyst or a top-tier firm's view before acting.
Documents Analyzed
Report based on filing metadata.
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
7d ago
|
Court Ruling
| $338.22 $345.46 | ▲ +2.14% | ▲ +1.74% | $345.73 (+2.22%) |
|
May 31, 2026
9d ago
|
ANALYST-DOWNGRADE
| $366.14 $368.86 | ▼ −0.74% | ▼ −0.72% | $345.73 (+5.57%) |
|
May 21, 2026
19d ago
|
ANALYST-UPGRADE
| $344.52 $345.77 | ▲ +0.36% | ▼ −0.66% | $345.73 (+0.35%) |
|
May 19, 2026
21d ago
|
8-K
| $331.63 $337.17 | ▲ +1.67% | ▲ +1.48% | $345.73 (+4.25%) |
|
May 1, 2026
5w ago
|
ANALYST-UPGRADE
| $311.11 $299.36 | ▼ −3.78% | ▼ −4.81% | $345.73 (+11.13%) |
|
Apr 22, 2026
6w ago
|
8-K
| $348.56 $344.53 | ▼ −1.16% | ▼ −1.94% | $345.73 (−0.81%) |
|
Apr 21, 2026
7w ago
|
ANALYST-UPGRADE
| $344.52 $345.77 | ▲ +0.36% | ▼ −0.66% | $345.73 (+0.35%) |
|
Apr 7, 2026
9w ago
|
DEFA14A
| $349.47 $355.35 | ▲ +1.68% | ▲ +1.11% | $345.73 (−1.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access